). Here we demonstrate that amiloride and EIPA inhibit the enzymatic activity of CVB3 3D pol in vitro, affecting both VPg uridylylation and RNA elongation. Examination of the mechanism of inhibition of 3D pol by amiloride showed that the compound acts as a competitive inhibitor, competing with incoming nucleoside triphosphates (NTPs) and Mg 2؉ . Docking analysis suggested a binding site for amiloride and EIPA in 3D pol , located in close proximity to one of the Mg 2؉ ions and overlapping the nucleotide binding site, thus explaining the observed competition. This is the first report of a molecular mechanism of action of nonnucleoside inhibitors against a picornaviral RNA-dependent RNA polymerase.
The family Picornaviridae is a family of positive-sense RNA viruses which contains numerous human pathogens, causing poliomyelitis, myocarditis, meningitis, hepatitis, the common cold, and other diseases. The viral genomic RNA is ϳ7,500 nucleotides (nt) long and contains a 22-amino-acid peptide, VPg, covalently linked to the 5Ј end and a poly(A) tail at the 3Ј end. Genome replication occurs via synthesis of a complementary, negative-sense RNA strand, catalyzed by the viral RNA-dependent RNA polymerase, 3D pol , in association with a number of viral and host proteins. It is a complex process taking place in membrane-associated replication complexes in the cytoplasm of infected cells (reviewed in references 5, 7, and 23). The synthesis of both complementary and genomic RNA strands is initiated by attachment of two UMP nucleotides to a tyrosine residue of VPg, resulting in the production of VPgpUpU. VPg uridylylation requires a template. In the case of genomic strand synthesis, an internal stem-loop in the genomic RNA strand (cis-acting replication element [CRE] ) is used as a template, with subsequent translocation of VPg-pUpU to the 3Ј end of the complementary strand and its elongation into a full-length genomic strand (9, 15, 16, 26) . The complementary strand synthesis does not absolutely depend on CRE-it can also be templated by the poly(A) tail of the genomic strand (9, 15, 16, 26) .
VPg uridylylation and RNA elongation have been reproduced successfully in vitro by use of purified components. VPg uridylylation assays require 3D pol , VPg, CRE or poly(A), UTP, and Mg 2ϩ or Mn 2ϩ (19, 20) , with CRE-templated reaction stimulated by viral proteins 3CD or 3C (18, 19) , whereas an elongation assay mix contains an RNA primer instead of VPg (21) .
Coxsackievirus B3 (CVB3) is a picornavirus responsible for 14 to 32% of human myocarditis cases (1) . Amiloride and its derivative 5-(N-ethyl-N-isopropyl)amiloride (EIPA) inhibit CVB3 propagation in cell culture by inhibiting viral genome replication (11) . Two amino acid substitutions in 3D pol (S299T and A372V) confer partial resistance of the virus to the compounds, suggesting that amiloride analogues may act as inhibitors of CVB3 3D pol (11) . Here we show that amiloride and EIPA inhibit VPg uridylylation and RNA elongation by CVB3 3D pol in vitro, acting as competitive inhibitors with respect to nucleoside triphosphates (NTPs) and Mg 2ϩ . We further demonstrate that the S299T substitution in 3D pol reduces the extent of inhibition of RNA elongation by amiloride and EIPA, thus recapitulating its effect on CVB3 inhibition in cell culture. This is the first report of a molecular mechanism of action of nonnucleoside inhibitors against a picornaviral RNA-dependent RNA polymerase. P]UTP were purchased from Perkin Elmer, and all other reagents were purchased from Sigma. Amiloride was dissolved in dimethyl sulfoxide (DMSO) at a 500 mM concentration, and EIPA was dissolved in ethanol at a 50 mM concentration. Final concentrations of DMSO and ethanol in reaction mixtures containing the compounds were 0.1% and 2%, respectively. Equal concentrations of the solvents were present in the no-compound controls.
VPg uridylylation assay using poly(A) template. The VPg uridylylation assay was conducted essentially as described previously (20) . Reaction mixtures contained 1.2 M CVB3 3D pol (WT or S299T mutant), poly(A) (equivalent of 70 M AMP), 50 M VPg, 10 M 32 P-labeled UTP (0.1 Ci/l), 50 mM HEPES-NaOH, pH 7.5, 6% glycerol, 11 mM 2-mercaptoethanol, 0.5 mM Mn(CH 3 COO) 2 , and the indicated concentrations of amiloride or EIPA. Reaction mixtures were assembled on ice without UTP and then incubated at 30°C for 5 min. Reactions were then started by addition of 32 P-labeled UTP and continued for 1 h at 30°C. The reactions were quenched by addition of EDTA to a final concentration of 50 mM, and reaction products were separated by 15% TrisTricine SDS-PAGE and quantified using a BAS-5000 phosphorimager (Fujifilm) with Multi Gauge software.
RNA elongation assay. SSU RNA was end labeled using [␥-32 P]ATP and T4 polynucleotide kinase (New England BioLabs), followed by purification on a Zeba 7K spin column (Pierce) equilibrated with water, as specified by the manufacturers' instructions. The resulting 20 M 32 P-labeled SSU was mixed with unlabeled SSU to a 200 M concentration and annealed by heating to 90°C for 1 min, followed by cooling to 10°C at 5°C/min.
Unless specified otherwise, reaction mixtures contained 1.8 M CVB3 3D pol (WT or S299T mutant), 20 M annealed 32 P-labeled SSU (10 M duplex), 10 M ATP, 5 mM MgCl 2 , 50 mM HEPES-NaOH, pH 7.5, 2% glycerol, 11 mM 2-mercaptoethanol, and the indicated concentrations of amiloride or EIPA. Reaction mixtures were assembled on ice and then incubated at 30°C. The orders of assembly of reaction mixtures and incubation times are indicated. Reactions were quenched by addition of an equal volume of 100 mM EDTA, 68% formamide, 0.02% bromphenol blue, and 0.02% xylene cyanol in TBE (89 mM Tris, 89 mM boric acid, 2 mM EDTA) and then heated to 65°C for 5 min prior to loading on a 20% polyacrylamide (1.5% bisacrylamide) gel containing TBE and 7% urea. The gels were visualized and quantified using a BAS-5000 phosphorimager (Fujifilm) with Multi Gauge software.
VPg uridylylation assay using CVB3 CRE template. Reaction mixtures contained 1 M 3D pol (WT or S299T mutant), 1 M CVB3 3C, 1 M CVB3 CRE, 50 M CVB3 VPg, 250 M 32 P-labeled UTP (0.1 Ci/l), 50 mM HEPESNaOH, pH 7.5, 10% glycerol, 12 mM 2-mercaptoethanol, 30 mM NaCl, 0.7 mM Mg(CH 3 COO) 2 , and the indicated concentrations of amiloride. Reaction mixtures were assembled on ice without 3D pol and incubated at 30°C for 5 min. Reactions were initiated by addition of 3D pol , continued for 5 min at 30°C, and quenched by addition of EDTA to a final concentration of 50 mM. Reaction products were separated by 15% Tris-Tricine SDS-PAGE and quantified using a Typhoon phosphorimager (GE Healthcare).
Molecular modeling. CVB3 and poliovirus 3D pol structures were downloaded from the Protein Data Bank (PDB; http://www.pdb.org/) and analyzed for docking suitability (i.e., model completeness, resolution, and visual analysis of conformational changes) by using Pymol (http://pymol.org/). Four alternate structures were used in the docking studies based on their docking suitability and the presence of cocrystallized ligands (i.e., Mg 2ϩ , ATP, or primer). These four had PDB codes 3CDW (10), 2ILY (24), 3OL7, and 3OL6 (8) . All structures were aligned by their ␣-carbons, and for each structure, water and nonphysiological ligands (i.e., detergents, salts, etc.) were removed. While aligned, the coordinates of the two Mg 2ϩ ions (crystallized in structure 3OL7 [8] ) and part of the VPg primer (crystallized in structure 3CDW [10] ) were extracted from their native crystal structure and merged into each alternate protein structure to create four different 3D pol models for each X-ray structure: apo, with Mg 2ϩ , with VPg, and with Mg 2ϩ and VPg. Each model was then minimized until gradient convergence was reached under the Merck molecular force fields (MMFFs).
The unprotonated form and the three protonated tautomers of amiloride and EIPA were drawn and minimized under the Tripos force field in Sybylx1.2 (Tripos). ATP was extracted from structure 2ILY and minimized under the Tripos force field in Sybylx1.2.
Docking protomers were constructed for each of the 16 alternate models in Surflex-Dock (Tripos). Each protomer was constructed by selecting a 15-Å sphere around Ser299, adding a bloat of 3 Å and a threshold of 0.36 (blind docking using the entire 3D pol molecule produced similar results). All ligands were docked into each protomer, with 5 additional starting conformations per molecule, ring flexibility considered, the density of search increased to 9.0 (default, 3.0), and hydrogen and heavy atom protein movement of the receptor allowed. All other parameters used were the defaults. The top 10 solutions were analyzed visually in Sybylx1.2 and Pymol, with all figures generated in Pymol.
RESULTS
Amiloride and EIPA inhibit poly(A)-templated VPg uridylylation. To examine the hypothesis that amiloride and EIPA act as CVB3 3D pol inhibitors (11), we assessed whether these compounds inhibit VPg uridylylation and/or RNA elongation by CVB3 3D pol in vitro. First, we conducted a VPg uridylylation and RNA elongation assay by using a poly(A) template (20) . The assay was performed on WT and S299T 3D pol in the presence of Mn 2ϩ (no product was observed in the presence of Mg 2ϩ ), using various concentrations of amiloride or EIPA or no compound.
Amiloride and EIPA reduced both VPg-pU(pU) and VPgpoly(U) production by WT and S299T 3D pol , in a concentration-dependent manner ( Fig. 1 ), demonstrating that they inhibit VPg uridylylation. EIPA had a stronger inhibitory effect than amiloride (Fig. 1B) , consistent with its stronger effect on CVB3 replication in cell culture (11) . S299T 3D pol was less susceptible to inhibition than WT 3D pol ( Fig. 1) , consistent with the previous finding that the S299T mutation confers partial resistance of CVB3 to the compounds (11) .
The effect of the compounds on VPg-poly(U) production appeared stronger than that on VPg-pU(pU) production (Fig.  1B) , which could mean that they inhibit RNA elongation. However, amiloride and EIPA had no obvious concentrationdependent effect on the length of the resulting poly(U) chain (Fig. 1A) , which is contrary to what is expected in the case of inhibition of RNA elongation. These results were therefore inconclusive regarding the inhibition of RNA elongation.
Amiloride and EIPA inhibit RNA elongation. To test whether amiloride and EIPA inhibit RNA elongation, we used a symmetrical, self-annealing, 10-nt RNA primer and template with uridine as the first templating base (SSU) (2):
ATP was used as the only nucleotide substrate to analyze single-nucleotide incorporation into SSU. In the presence of Mg 2ϩ , 3D pol binds to the SSU duplex and incorporates a single AMP at the 3Ј terminus of one RNA strand, with rapid, presteady-state burst kinetics (2, 3). This is followed by slow dissociation of 3D pol from the product (rate-limiting step of the steady-state phase) and subsequent rebinding to a new SSU duplex followed by AMP incorporation (2) .
We measured the steady-state kinetics of 11-nt RNA production (formed by the addition of one AMP molecule to the 10-nt RNA primer) by WT and S299T 3D pol in the absence or presence of various concentrations of amiloride or EIPA. 3D pol was preincubated with SSU duplex (used in a 5.5-fold excess of 3D pol ) and the test compounds in the presence of Mg 2ϩ for 6 min at 30°C, after which reactions were initiated by addition of ATP, continued for 10, 18, 26, or 34 min, and then quenched ( Fig. 2A) . The amount of AMP incorporated into SSU during the pre-steady-state burst was determined by plotting 11-nt RNA production in each reaction as a function of VOL. 85, 2011 AMILORIDE IS A COMPETITIVE INHIBITOR OF CVB3 3D pol the reaction time and fitting the data points to a line. The y intercept of each line defined the amount of AMP incorporated during the pre-steady-state burst (Fig. 2B ). Both compounds inhibited the amplitude of the pre-steady-state burst in a concentration-dependent manner (Fig. 2C) , thus demonstrating that they inhibited RNA elongation. EIPA had a stronger effect on the pre-steady-state burst of AMP incorporation than did amiloride, and WT 3D pol was more susceptible to the inhibition than S299T 3D pol (Fig. 2C) , consistent with the data on CVB3 replication in cell culture (11) . The difference in susceptibility to inhibition between WT and S299T 3D pol (3.6-fold difference in 50% inhibitory concentration [IC 50 ] for amiloride and 4.4-fold difference for EIPA) (Fig. 2) was significantly more pronounced than that observed for VPg-pU(pU) production (1.3-and 2-fold differences in IC 50 for amiloride and EIPA, respectively) (Fig. 1) . 2 , and the indicated concentrations of amiloride or EIPA. Reactions were started by addition of UTP, and mixtures were incubated at 30°C for 1 h. Reaction products were then separated by gel electrophoresis, and VPg-pU(pU) and VPg-poly(U) production was quantified using a phosphorimager. (A) Representative gel images. Positions of UTP, VPg-pU(pU), and VPg-poly(U) are marked. (B) Dose-response curves for amiloride (left) and EIPA (right). f, VPg-pU(pU) production by WT 3D pol ; OE, VPg-poly(U) production by WT 3D pol ; Ⅺ, VPg-pU(pU) production by S299T 3D pol ; ‚, VPgpoly(U) production by S299T 3D pol . IC 50 , 50% inhibitory concentrations calculated using the equation y ϭ 100/{1 ϩ 10 [(log IC 50 Ϫ log X) ϫ hill slope]} (GraphPad Prism). The data points are means Ϯ standard errors of the means (SEM) for 3 independent experiments.
In contrast to inhibition of the pre-steady-state burst amplitude, the effects of the compounds on the steady-state rate constant were small (data not shown) and difficult to interpret due to the occurrence of multiple events (i.e., dissociation, association, and nucleotide incorporation). Our following studies were therefore focused on the pre-steady-state burst amplitude.
Inhibitory effect on RNA elongation depends on the order of addition. As a first step toward elucidation of the mechanism We preincubated 3D pol with SSU and the test compounds in the absence of Mg 2ϩ for 6 min at 30°C, after which reactions were started by the addition of ATP and Mg 2ϩ . Dose-response curves for the inhibition of pre-steady-state burst amplitude (Fig. 3) were obtained as described above. The results showed that amiloride and EIPA were ϳ7-fold more effective when they were incubated with SSU and WT 3D pol in the absence of Mg 2ϩ prior to ATP addition than when they were incubated in the presence of Mg 2ϩ ( Fig. 3 and 2C ). This result suggested that the compounds might compete with Mg 2ϩ for the binding site. The difference between WT and S299T 3D pol was also more pronounced under these conditions (5.9-fold for amiloride and 5.8-fold for EIPA) (Fig. 3) .
Further order-of-addition experiments were conducted with WT 3D pol , using 500 M amiloride. Adding amiloride to preassembled SSU-3D pol complexes (order of addition, SSU ϩ 3D pol ϩ Mg 2ϩ 3 amiloride 3 ATP) resulted in 80% inhibition of pre-steady-state AMP incorporation into SSU, compared to 84% inhibition when amiloride was added prior to the complex assembly (Table 1 ). This result showed that amiloride can bind to SSU-3D pol complexes and that it is unlikely to affect complex formation.
Adding amiloride at the same time as ATP in the presence of Mg 2ϩ (order of addition, SSU ϩ 3D pol ϩ Mg 2ϩ 3 ATP ϩ amiloride) reduced the extent of inhibition from 84% to 9% (Table 1 ). This suggested that amiloride might compete with ATP for the binding site. However, adding amiloride at the same time as ATP in the absence of Mg 2ϩ (order of addition, SSU ϩ 3D pol ϩ ATP ϩ amiloride 3 Mg 2ϩ ) resulted in 96% inhibition, the same effect as when the compound was added prior to ATP (order of addition, SSU ϩ 3D pol ϩ amiloride 3 ATP ϩ Mg 2ϩ ) ( Table 1 ). The dependence of the inhibitory effect of amiloride added together with ATP on the order of Mg 2ϩ addition indicated that amiloride may interact with 3D pol slower than does ATP. In this case, in the presence of Mg 2ϩ , the chemical reaction of AMP incorporation into SSU would occur too fast to be inhibited by amiloride, whereas the 6-min incubation in the absence of Mg 2ϩ would allow amiloride to compete with ATP.
Altogether, the order-of-addition experiments suggested that amiloride may be a slow-binding inhibitor competing with ATP and Mg 2ϩ . Amiloride is a slow inhibitor. To examine the kinetics of 3D pol inhibition by amiloride, we assembled SSU-3D pol complexes and incubated them with amiloride for various periods in the presence of Mg 2ϩ prior to starting reactions with ATP. The inhibitory effect of amiloride on both WT and S299T
FIG. 3. Effect of order of Mg
2ϩ addition on inhibition of pre-steady-state AMP incorporation into SSU by amiloride and EIPA. A total of 1.8 M CVB3 3D pol (WT or S299T) was preincubated with 20 M 32 P-labeled SSU and the indicated concentrations of amiloride or EIPA for 6 min at 30°C. Reactions were started by addition of 10 M ATP and 5 mM MgCl 2 . The pre-steady-state burst amplitude of AMP incorporation into SSU was measured and quantified as described in the legend to Fig. 2 . IC 50 , 50% inhibitory concentrations calculated using the equation y ϭ 100/{1 ϩ 10 [(log IC 50 Ϫ log X) ϫ hill slope]} (GraphPad Prism). f, WT 3D pol plus amiloride; OE, WT 3D pol plus EIPA; Ⅺ, S299T 3D pol plus amiloride; ‚, S299T 3D pol plus EIPA. The data points are averages Ϯ SEM for 3 independent experiments. Fig. 2C . b Presented in Fig. 3 .
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pol gradually increased with the increase in incubation time (Fig. 4) . The calculated inhibition half-time values were ϳ35 s for WT 3D pol with 500 M amiloride and S299T 3D pol with 1,000 M amiloride and ϳ70 s for WT 3D pol with 250 M amiloride and S299T 3D pol with 500 M amiloride (Fig. 4) . These data demonstrated that amiloride inhibits 3D pol slowly, possibly due to steric constraints of the binding site or to a conformational change occurring in the process. They also showed that S299T 3D pol is inhibited 2-fold slower than WT 3D pol by the same concentration of amiloride, consistent with the partial resistance to inhibition of RNA elongation conferred by this mutation.
Amiloride competes with ATP and Mg 2؉ . To test the hypothesis that amiloride may compete with NTPs for the binding site on 3D pol , we conducted a competition assay with the WT enzyme, using various concentrations of ATP and amiloride. We incubated 3D pol , SSU, amiloride, and ATP for 5 min at 30°C in the absence of Mg 2ϩ to allow binding, after which reactions were started by the addition of 5 mM MgCl 2 . The amplitude of pre-steady-state AMP incorporation into SSU was quantified and plotted as a function of ATP concentration ( Fig. 5A and B) . The data showed that the inhibitory effect of amiloride decreased with increases in ATP concentration (Fig. 5B) , suggesting that amiloride competes with ATP for the binding site. This result also demonstrated that Mg 2ϩ is not required for binding of SSU, ATP, and amiloride to 3D pol (otherwise competition between ATP and amiloride would not be observed under these conditions).
A similar competition assay was conducted using various concentrations of Mg 2ϩ and amiloride to test the hypothesis that amiloride may compete with Mg 2ϩ for the binding site. WT 3D pol , SSU, amiloride, and Mg 2ϩ were incubated for 5 min at 30°C, after which reactions were started by the addition of 10 M ATP (Fig. 5C and D) . The results were more complicated to interpret than those from the ATP competition assay, perhaps because the stoichiometry of the complexes involves two Mg 2ϩ ions at two functionally distinct sites (see Fig. 8 ). With amiloride concentrations of 50 and 125 M, the inhibition decreased with an increase in Mg 2ϩ concentration from 0.5 to 3.5 mM (Fig. 5D) . The response was saturated above 3.5 mM Mg 2ϩ , as evidenced by the leveling off of the line (Fig. 5D) . A 500 M amiloride concentration was too high to observe a significant effect of Mg 2ϩ concentration on the level of inhibition by amiloride (Fig. 5D) . In total, these data are consistent with competition between amiloride and Mg 2ϩ for binding to 3D pol . Note that the effect of Mg 2ϩ concentration on the enzymatic activity of 3D pol in the absence of amiloride (i.e., a concentration-dependent increase in AMP incorporation followed by a decrease [ Fig. 5C]) is a pattern for optimum Mg 2ϩ concentration observed in nucleic acid polymerases, including CVB3 3D pol (10) . Amiloride inhibits CRE-templated VPg uridylylation. The above results suggested that amiloride inhibits RNA elongation by acting as a competitive inhibitor with respect to NTPs and Mg 2ϩ . The VPg uridylylation assay using a poly(A) template indicated that amiloride also inhibits VPg uridylylation, but that assay could be done only by using Mn 2ϩ instead of Mg 2ϩ . We therefore examined inhibition of VPg uridylylation by amiloride under more biologically relevant conditions by using CRE template in the presence of Mg 2ϩ (17) . The assay was conducted on WT and S299T 3D pol . Reaction mixtures including CVB3 3C, CVB3 CRE, CVB3 VPg, 250 M UTP, 0.7 mM Mg 2ϩ , and various concentrations of amiloride were incubated at 30°C for 5 min. Reactions were initiated by the addition of 3D pol , incubated for 5 min, and then quenched. Concentrations of 250 M UTP and 0.7 mM Mg 2ϩ correspond FIG. 4 . Dependence of inhibitory effect of amiloride on incubation time before ATP addition. Amiloride was added to preassembled SSU-3D pol complexes and incubated at 30°C for the indicated periods prior to the start of reactions by addition of 5 mM ATP. The reactions were allowed to proceed for 20 s, after which the 11-nt product was separated from SSU by gel electrophoresis and its amount was quantified using a phosphorimager. Product formation, normalized to no-amiloride controls, was plotted as a function of incubation time before ATP addition. Lines are fits to the single exponential model P ϭ A ϫ exp(Ϫk obst ϫ t) ϩ C, where A is the amplitude, k obs is the observed rate constant, t is the independent variable time, and C is the endpoint. Inhibition half-times were calculated as ln 2/k obs . OE, WT 3D pol plus 250 M amiloride; f, WT 3D pol plus 500 M amiloride; Ⅺ, S299T 3D pol plus 500 M amiloride; ᭛, S299T 3D pol plus 1 mM amiloride. The data points are averages Ϯ SEM for 2 independent experiments.
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pol to the physiological concentrations of UTP and free Mg 2ϩ in mammalian cells (22, 25) . The results demonstrated that amiloride effectively inhibited VPg uridylylation under these conditions (Fig. 6) , with the IC 50 being lower than that for VPg uridylylation using the poly(A) template (Fig. 1) . Surprisingly, there was no difference in inhibitory effect between WT and S299T 3D pol (Fig. 6 ). Changing the experimental conditions, such as the incubation time, UTP and Mg 2ϩ concentrations (i.e., using 10 M UTP and 5 mM Mg 2ϩ ), and order of addition (i.e., starting the reaction with UTP and Mg 2ϩ ), produced similar results to those shown in Fig. 6 (data not shown) .
Molecular basis of inhibition. CVB3 and poliovirus 3D pol structures (3CDW, 2ILY, 3OL6, and 3OL7) were downloaded from the Protein Data Bank and analyzed for docking suitability. Similar docking results were obtained irrespective of which 3D pol structure was used or whether unprotonated amiloride and EIPA or their protonated tautomers were docked. Thus, for simplicity, only the unprotonated forms of EIPA and amiloride docked into structures based on the 3CDW entry are described in detail.
Amiloride and EIPA were able to dock into each of the four 3D pol structures: apo, with Mg 2ϩ , with VPg, and with Mg 2ϩ and VPg (Table 2) . Notably, when Mg 2ϩ ions were present, a consistent binding pose was not observed for either compound, suggesting that Mg 2ϩ inhibits compound binding. Also, when Mg 2ϩ was present, the Surflex scoring function, the C score (a unitless con- sensus score which integrates a number of popular scoring functions to indicate the affinity of ligands bound to a receptor), was significantly reduced for the top docked solution (Table 2) .
Where a consistent solution was obtained (apo and VPg configurations of 3D pol ), both amiloride and EIPA docked with hydrogen bonds to amino acid residues Ala57, Ser173, Ser60, and Lys61 (Fig. 7) . The amino group of amiloride, which is capped by a branched carbon chain (i.e., N-ethyl-Nisopropyl group) in EIPA, hydrogen bonded to Ser289. Hydrophobic interactions were found between EIPA or amiloride and Ala57, Ile58, Lys172, Ser173, and Arg174. Additional hydrophobic interactions were found between the N-ethyl-N-isopropyl group of EIPA and Lys61, Asp238, and Ser289 (Fig. 7) . The carbonylguanidino moiety of each compound was found in two possible orientations due to its flexibility. The C scores for both orientations were very similar, and thus both are plausible solutions. However, one orientation (Fig. 7A) had a higher C score for EIPA (7.7121 versus 7.217), whereas the alternative orientation (Fig. 7B) had a higher C score for amiloride (7.3372 versus 7.087).
The position of docked amiloride or EIPA was distinct from where VPg and the RNA template interact with 3D pol (8) , suggesting that the presence of RNA template and/or VPg should not have a significant effect on binding (Table 3 and Fig.  8 ). This was consistent with our finding that amiloride can bind to preassembled SSU-3D pol complexes. Amiloride and EIPA were also distant from Ser299 (and Ala372) ( Table 3 ). Our data showing that the S299T mutation affects inhibition of RNA elongation but not CRE-templated VPg uridylylation by amiloride are consistent with Ser299 not being part of the compound's binding site.
The pyrazine ring of amiloride and EIPA was very close to the binding site of one of the Mg 2ϩ ions causing repulsive interactions (Table 3 and (Table 2 ). This was enhanced for EIPA because its N-ethyl-N-isopropyl group encroached on the position of the Mg 2ϩ ion (Table 3 and Fig. 8 ). ATP docked into the same position in all 3D pol configurations (i.e., apo, with Mg 2ϩ , with VPg, and with VPg and Mg 2ϩ ), in an orientation observed in the crystal structures (Fig. 8) . There was overlap between the binding site of ATP and the binding sites of amiloride and EIPA (Fig. 8) , suggesting that the compounds compete with NTPs for binding to 3D pol . The docking score of ATP was significantly higher than that of amiloride or EIPA ( Table 2 ), suggesting that ATP binds to 3D pol with a higher affinity than that of amiloride or EIPA.
DISCUSSION
Amiloride and EIPA have been shown to inhibit CVB3 RNA replication in cell culture, with amino acid substitutions in 3D pol (S299T or A372V) conferring partial resistance of CVB3 to the compounds, suggesting that the antiviral effect of the compounds may be due to 3D pol inhibition (11) . Here we demonstrated that amiloride and EIPA inhibit VPg uridylylation and RNA elongation by CVB3 3D pol in vitro. Examination of the mechanism of inhibition of 3D pol by amiloride showed that the compound acts as a competitive inhibitor, competing with incoming NTPs and Mg 2ϩ (Fig. 5) . Docking analysis suggested the most likely binding site for amiloride and EIPA in 3D pol (Fig. 8) . Binding of the compounds at this site would interfere with binding of NTPs and one of the Mg 2ϩ ions, thus explaining the observed competition (Fig. 8) .
Previous studies have shown that amiloride inhibits a number of protein kinases via competition with ATP (4, 6, 12) . Thus, this compound has affinity for the nucleotide binding sites of different enzymes.
Compared to amiloride, EIPA was a more potent 3D pol inhibitor ( Fig. 1 to 3 ), consistent with its stronger effect on WT CVB3 replication in cell culture (11) . The docking analysis suggested that this was due to the additional hydrophobic interactions between the branched carbon chain of EIPA and three amino acid residues of 3D pol (Fig. 7) . The difference between amiloride and EIPA in the inhibition of CVB3 replication in cell culture (30-fold difference in IC 50 [11] ) was more pronounced than that in the inhibition of CVB3 3D pol in the in vitro assays, likely due to different intracellular accumulation of the two compounds. a All measurements are an indication of heavy atom distances from the ligand to the closest heavy atom in the substructure.
VPg uridylylation and RNA elongation, with RNA elongation being the main process rescued by the S299T mutation in 3D pol . The compounds act as competitive inhibitors of CVB3 3D pol , competing with NTPs and Mg 2ϩ for binding to the active site of the enzyme. This is the first report of a molecular mechanism of action of nonnucleoside inhibitors against a picornaviral RNA-dependent RNA polymerase.
